Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

Fivefold difference found in Medicaid reimbursements for radiotherapy May limit access to healthcare, especially in rural areas

Trends in radiation oncology workforce potentially threaten rural patients, says study More radiation oncologists leaving, fewer coming in to rural areas

Varian showcases first preclinical findings of Flash therapy trial Reductions in radiation lung fibrosis and dermatitis

Female oncologists submit fewer charges, paid less than male Study bases findings on Medicare records

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

Q&A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Israeli startup Alpha Tau Medical raises $29 million for novel radiotherapy

by Thomas Dworetzky , Contributing Reporter
Alpha Tau Medical, developer of Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT), has raised $29 million in private money in a round led by Israeli private equity firm Shavit Capital.

The late-stage investor was part of a round that included crowdfunding platform OurCrowd.com, Medison Ventures, and Sir Ronald Cohen and Alan Patricof, founders of Apax Partners.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

"We are excited by the strong support provided by these distinguished investors," Alpha Tau's CEO Uzi Sofer said in a statement. "The funding will be invaluable to explore the full potential of the Alpha DaRT as a cancer treatment for clinical trials worldwide, as well as establish global production facilities for the radioactive DaRT seeds to meet local distribution demand."

The investment comes on the heels of the Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), approving Alpha DaRT cancer treatment as a Sealed Source and Device (SSD), and safe for clinical trials.

It is the first alpha radiation-based cancer treatment for various types of solid tumors, administering high-precision, soft-range alpha particles that effectively destroy cancer cells while sparing surrounding healthy tissue.

The particles are inserted into the tumor using ultra-minimally-invasive applicators created to reach various types of tumors in different anatomic areas.

As the radioactive material inside decays, it releases alpha radiation inside the tumor, breaking the DNA in ways that destroy cancer cells.

“The Alpha DaRT applicators are designed to ensure that the Alpha DaRT seeds and the radioactive isotopes will be released only inside of the tumor in a way that will eliminate the risk of unnecessary exposure to the patient or the medical staff,” Amnon Gat, chief operations officer for Alpha Tau Medical, told HCB News in August. “The sealing mechanisms of the Alpha DaRT devices were tested under extreme environmental conditions that are required by ISO 2919, such as high temperature, pressure, impact and bending."

Early clinical trials have shown that Alpha DaRT is safe and effective for squamous cell carcinoma tumors – with all patients seeing tumor reduction and over 70 percent having tumors disappear within days of therapy.

"We are confident that Alpha Tau's groundbreaking technology can be a game changer in the treatment of cancer,”said Shavit Capital founder and managing partner Gary Leibler, stressing that the firm's experienced team had succeeded in forming “strategic relationships and trials with leading international medical research centers,” which position it to become a global power in next-gen cancer radiation therapies.

Meir Jakobsohn, the founder and CEO of Medison Pharma – one of the firm's first investors – added that his firm was “very optimistic about the Alpha DaRT's potential to activate the immune system and to become a valid treatment option for metastatic cancer.”

Clinical trials are now underway for Alpha DaRT using varied protocols across a number of cancers, including pancreatic, breast, head and neck, gynecological, and prostate.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.